在食堂饮食诱导的肥胖大鼠中,西布拉明的高剂量影响
Filipe M Ribeiro1,2, Henny K Lima1, Camila F A Ribeiro3
1Center for Proteomics and Biochemical Analysis, Postgraduate Program in Genomic Sciences and Biotechnology, Catholic University of Brasília, Brasília, Brazil.
Scientific reports
|February 11, 2026
概括
在大鼠中,高剂量西布胺显著降低了体重,并改善了代谢健康. 这种肥胖药物也对肠道微生物群产生了积极的影响,部分扭转了饮食引起的失生症.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 微生物学 微生物学
背景情况:
- 肥胖是一个全球性健康危机,死亡率很高.
- 西布胺是一种厌食剂,在退出市场之前,它是治疗肥胖症的关键药物治疗方法.
- 了解sibutramine对代谢健康和肠道微生物群的影响至关重要.
研究的目的:
- 评估高剂量西布拉明对食堂饮食的老鼠体重,生物化学概况,肝脏和肠道健康以及肠道微生物群的影响.
- 调查西布拉明在减轻饮食引起的肥胖和相关健康问题方面的潜力.
主要方法:
- 鼠被用餐厅的饮食养了16周.
- 使用高剂量西布拉明 (10 mg/kg/天,其次是 13 mg/kg/天)
- 分析了体重,生化标志物,肝酶 (AST,ALT),肠道形态和肠道微生物群组成.
主要成果:
- 西布胺治疗导致10.93%的体重减轻和改善血糖控制.
- 脂质概况被调节,控制饮食组的总胆固醇降低,HDL增加.
- 肝损伤标志物减弱,肠道密室深度增加,表明肠道完整性得到改善.
- 西布特拉明部分逆转了食堂饮食引起的肠道失调,增加了SCFA产生细菌,如Bacillus,Marvinbryantia和Bifidobacterium.
结论:
- 高剂量的sibutramine有效地降低了体重,并改善了肥胖模型中的代谢参数.
- 西布拉明治疗对肠道完整性和微生物群组成产生积极影响,部分抵消饮食诱导的失生症.
- 饮食因素仍然是肠道微生物组成的主要驱动因素,但sibutramine剂量会影响这些变化.
相关概念视频
Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Insulin: Dosing Regimen and Adverse Effects
835
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
835
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Biological Effects of Radiation
18.1K
All radioactive nuclides emit high-energy particles or electromagnetic waves. When this radiation encounters living cells, it can cause heating, break chemical bonds, or ionize molecules. The most serious biological damage results when these radioactive emissions fragment or ionize molecules. For example, α and β particles emitted from nuclear decay reactions possess much higher energies than ordinary chemical bond energies. When these particles strike and penetrate matter, they...
18.1K
Dose Size and Dosing Frequency: Determination Methods
328
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
328
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
250
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
250


